18F-FLT PET/CT显像IV期皮肤黑色素瘤增殖:预测靶向治疗耐药的潜在无创工具?
该研究为II期多中心REPOSIT试验的探索性附属研究,纳入19例IV期BRAF V600E/K突变皮肤黑色素瘤患者,在基线及治疗2周后行18F-FLT PET/CT,基线行18F-FDG PET/CT对比。结果示基线18F-FLT摄取持续低于18F-FDG者PFS较长,2周时18F-FLT摄取下降百分比更大与更长PFS相关。作者认为18F-FLT PET/CT可能具有预测价值,需更大前瞻性研究确认。
要点
- 基线18F-FLT持续低于18F-FDG者中位PFS 9.6个月,等于/高于或异质性者3.5至5.3个月。
- 2周时18F-FLT摄取下降百分比更大者中位PFS 13.9个月 vs 4.3个月(P=0.005)。
- 基线18F-FLT SULpeak与Ki67表达无相关性(P=0.601),Ki67与PFS亦无关(P=0.39)。
核心结论
- 基线18F-FLT相对于18F-FDG的摄取模式及18F-FLT摄取的早期变化与接受BRAF/MEK抑制剂治疗患者的PFS相关。
- 这些探索性发现提示18F-FLT PET/CT可能具有预测价值,需在更大前瞻性研究中确认。
研究设计与样本
- II期多中心REPOSIT试验的探索性附属研究,纳入19例IV期BRAF V600E/K突变皮肤黑色素瘤患者,行可选18F-FLT PET/CT。
- 18F-FLT PET/CT于基线及治疗2周后 performed,基线行18F-FDG PET/CT对比,并评估转移组织样本Ki67表达。
主要发现
- 基线18F-FLT持续低于18F-FDG者中位PFS 9.6个月(范围3.4至32.3),等于/高于或异质性18F-FLT摄取者中位PFS 3.5至5.3个月。
- 基线18F-FLT SULpeak与Ki67表达无相关性(P=0.601),Ki67与PFS亦无关联(P=0.39)。
- 基线18F-FLT SULpeak低于或高于中位数者之间PFS无显著差异(P=0.601)。
- 2周时18F-FLT摄取下降百分比更大与更长PFS相关(中位13.9 vs 4.3个月,P=0.005)。
关键数值与推荐
- 基线18F-FLT持续低于18F-FDG者中位PFS 9.6个月(范围3.4至32.3),等于/高于或异质性者3.5至5.3个月。
- 2周时18F-FLT摄取下降百分比更大者中位PFS 13.9个月 vs 4.3个月(P=0.005)。
- 基线18F-FLT SULpeak与Ki67无相关性(P=0.601);Ki67与PFS无关联(P=0.39);基线18F-FLT SULpeak低于或高于中位数者PFS无显著差异(P=0.601)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文为探索性附属研究,样本量19例。
- 作者指出这些探索性发现需在更大前瞻性研究中确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: 18 F-FLT PET/CT visualizes cellular proliferation and may correlate more directly with tumor aggressiveness and treatment response than 18 F-FDG PET/CT in melanoma patients treated with BRAF/MEK inhibitors. We aimed to assess whether 18 F-FLT PET/CT can predict early resistance to BRAF/MEK inhibitors in addition to current clinical tools in patients with BRAF-mutated metastatic melanoma. PATIENTS AND METHODS: This explorative side study of the phase II multicenter REPOSIT trial included 19 patients with stage IV BRAF V600E/K-mutated cutaneous melanoma who underwent optional 18 F-FLT PET/CT. 18 F-FLT PET/CT was performed at baseline and after 2 weeks of treatment to evaluate baseline uptake and early changes in metabolic activity. 18 F-FDG PET/CT was performed at baseline for comparison. Ki67 expression was assessed in metastatic tissue samples. Analyses included: (1) visual comparison of baseline 18 F-FLT and 18 F-FDG uptake, (2) correlation of 18 F-FLT uptake with Ki-67, (3) semiquantitative analysis of baseline 18 F-FLT uptake, and (4) evaluation of percentage change in 18 F-FLT uptake after 2 weeks. RESULTS: Patients with consistently lower 18 F-FLT than 18 F-FDG uptake in metastases had longer progression-free survival (PFS; median 9.6 months, range: 3.4 to 32.3) compared with those with equal/higher or heterogeneous 18 F-FLT uptake (3.5 to 5.3 mo). Baseline 18 F-FLT SULpeak did not correlate with Ki67 expression ( P = 0.601), nor was Ki67 associated with PFS ( P = 0.39). No significant PFS difference was observed between patients with baseline 18 F-FLT SULpeak below or above the median ( P = 0.601). However, a greater percentage decrease in 18 F-FLT uptake at 2 weeks was associated with longer PFS (median: 13.9 vs 4.3 mo, P = 0.005). CONCLUSIONS: Baseline 18 F-FLT uptake patterns relative to 18 F-FDG, and early changes in 18 F-FLT uptake, were associated with PFS in patients treated with BRAF/MEK inhibitors. These explorative findings suggest that 18 F-FLT PET/CT may have predictive value, warranting confirmation in larger prospective studies.
引用
- van der Hiel B, Vogel WV, van den Eertwegh AJM, et al. Imaging Proliferation of Stage IV Cutaneous Melanoma With 18 F-FLT PET/CT : A Potential Noninvasive Tool for Predicting Treatment Resistance to Targeted Therapy? Clin Nucl Med. 2025. PMID: 40424608. doi:10.1097/RLU.0000000000005999
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。